xRead - September 2022

Wise et al.

Page 430

Improvement of PC 20 in all groups. No PC 20 improvement with INCS and inhaled steroid vs inhaled FP alone. No change in Asthma QOL. FeNO and nPIF reduced only with INCS.

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE X.A.4-2. Study

INCS improved FEV1, PC 20 , asthma symptom scores, and rescue medication use. No asthma outcome changes with INCS plus oral inhaled CS vs oral inhaled CS alone. Nasal inhaled CS improved PEF.

design Study groups Clinical endpoint Conclusion

Nonsignificant symptom improvement INCS vs placebo. No difference in FEV1, PEF, PC 20 , and PD 20 .

Reduction in asthma symptom severity score and increase in PEF with FP INCS vs montelukast.

Exercise induced decrease in FEV1 reduced with FP. No difference in FEV1, ACQ, PAQLQ, FeNO.

GS score reduction with MF INCS. LA score decreased with MF INCS. No difference MFNS vs placebo for rescue medications.

exacerbation events, QOL, FEV1, PEF, PC 20 , and PD 20 , inflammatory markers

Asthma symptoms and β - agonist use, asthma

Methacholine PC 20 , FeNO,

QOL by GS; symptom scores; Rhinasthma scores of RAI, LA, and UA a , rescue asthma medication use

Asthma symptoms, rescue medication use, FEV1, PEF, PC 20 , QOL

nPIF, FEV1, asthma and rhinitis QOL

Symptom scores of rhinitis and asthma, PEF

Change in exercise induced decrease in FEV1, change in AUC of the FEV1 curve,

ACQ score, PAQLQ score, FeNO

Baiardini et al. 1833 2010 1b DBRCT Moderate/severe persistent AR with intermittent asthma (n = 47): 1 MF INCS 200 μ g per day; 2 Placebo Persistent AR and asthma (n = 25): 1 Inhaled FP 100 μ g, inhaled placebo, placebo nasal spray; 2 Inhaled FP 100 μ g, inhaled placebo, FP INCS; 3 Inhaled FP 500 μ g, inhaled placebo, placebo nasal spray

1 FP INCS 200 μ g twice daily;

1 INCS spray vs placebo; 2 INCS spray plus oral inhaled CS vs oral inhaled CS alone; 3 Nasal inhaled CS vs placebo 1 INCS vs placebo;

2 INCS vs conventional asthma treatment;

3 INCS plus conventional vs conventional alone 2 Montelukast 10 mg at night

Kersten et al. 1789 2012 1b DBRCT AR and mild-to-moderate exercise exacerbated asthma (n = 32): 1 Fluticasone furoate INCS; 2 Placebo double dummy, 3 way crossover

18 RCTs (n = 2162):

14 RCTs with 3 interventions:

AR and asthma (n = 120):

meta

analysis

analysis

blind

Evidence for intranasal corticosteroids for the treatment of asthma in the context of coexistent allergic rhinitis Study Year LOE Lohia et al. 1296 2013 1a SR and Taramarcaz & Gibson 1295 2003 1a Meta Jindal et al. 1832 2016 1b RCT, single Nair et al. 1834 2010 1b DBRCT,

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.